Larimar Therapeutics
LRMR
87 hedge funds and large institutions have $260M invested in Larimar Therapeutics in 2018 Q2 according to their latest regulatory filings, with 36 funds opening new positions, 25 increasing their positions, 14 reducing their positions, and 10 closing their positions.
298% more call options, than puts
Call options by funds: $526K | Put options by funds: $132K
260% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 10
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
128% more capital invested
Capital invested by funds: $114M → $260M (+$146M)
79% more repeat investments, than reductions
Existing positions increased: 25 | Existing positions reduced: 14
43% more funds holding
Funds holding: 61 → 87 (+26)
3.02% more ownership
Funds ownership: 4.63% → 7.65% (+3%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$24.8M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
+$8.97M |
| 3 |
BlackRock
New York
|
+$7.53M |
| 4 |
AC
Armistice Capital
New York
|
+$4.25M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
+$3.47M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NC
Nexthera Capital
New York
|
-$2.99M |
| 2 |
Man Group
London,
United Kingdom
|
-$1.02M |
| 3 |
Goldman Sachs
New York
|
-$725K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$724K |
| 5 |
BCM
BlueCrest Capital Management
St Helier,
Jersey
|
-$512K |
LRMR Hedge Fund Activity: Q2 2018 in Review
87 of the 4,385 institutional investors tracked by Wall St. Rank reported a position in Larimar Therapeutics (LRMR) for Q2 2018, worth a combined $260M — up 128% from $114M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new LRMR positions and 10 closed out — a net gain of 26 holders — while 25 added to existing stakes and 14 trimmed.
The largest buyer was Great Point Partners, opening a new position worth an estimated $24.8M. The largest seller was Nexthera Capital, exiting entirely with an estimated $2.99M sold.
- 87 institutional investors held Larimar Therapeutics (LRMR) as of Q2 2018, up from 61 in Q1 2018.
- Funds reported $260M of Larimar Therapeutics stock for Q2 2018, up 128% quarter-over-quarter.
- 36 funds opened new Larimar Therapeutics positions in Q2 2018 and 10 closed out, a net change of +26 holders.
- The largest Larimar Therapeutics buyer in Q2 2018 was Great Point Partners, an estimated $24.8M added.
- The largest Larimar Therapeutics seller in Q2 2018 was Nexthera Capital, an estimated $2.99M sold.
Based on aggregated 13F filings for Q2 2018.